Jieni Li to United States
This is a "connection" page, showing publications Jieni Li has written about United States.
Connection Strength
0.381
-
Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States. Prev Med. 2025 Jan; 190:108180.
Score: 0.197
-
Marginal health care expenditures for melanoma care in the United States. J Manag Care Spec Pharm. 2024 Dec; 30(12):1364-1374.
Score: 0.049
-
Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease. Arch Gerontol Geriatr. 2025 Jan; 128:105629.
Score: 0.049
-
Incremental health care expenditures for non-Hodgkin lymphoma in comparison with other cancers: Analysis of national survey data. J Manag Care Spec Pharm. 2023 May; 29(5):480-489.
Score: 0.044
-
Improving utility of prescription drug monitoring programs with more accurate patient information. Fam Pract. 2022 Jul 19; 39(4):773-774.
Score: 0.042